Cinclus Pharma Holding AB financials
Cinclus Pharma Holding AB
549300TJBPSNZ3DO6B42 | Line item | 2024 | 2023 |
|---|---|---|
| Income statement | ||
| Other income | SEK 2.8M | SEK 77.0K |
| Operating profit (EBIT) | -SEK 169.6M | -SEK 201.0M |
| Net finance income / (cost) | SEK 2.4M | -SEK 13.6M |
| Finance costs | SEK 28.1M | SEK 17.2M |
| Profit before tax | -SEK 167.3M | -SEK 214.6M |
| Profit for the year | -SEK 168.0M | -SEK 215.1M |
| Total comprehensive income | -SEK 165.4M | -SEK 206.0M |
| Per share | ||
| Basic EPS | SEK -4.54 | SEK -8.20 |
| Diluted EPS | SEK -4.54 | SEK -8.20 |
| Cash flow statement | ||
| Net cash from operating activities | -SEK 178.4M | -SEK 209.2M |
| Income taxes paid | SEK 7.4M | SEK 6.8M |
| Net cash from financing activities | SEK 655.2M | SEK 122.9M |
| Lease liability payments | SEK 1.4M | SEK 1.3M |
| Net change in cash | SEK 476.8M | -SEK 86.3M |
| Balance sheet | ||
| Total assets | SEK 601.0M | SEK 94.4M |
| Non-current assets | SEK 546.0K | SEK 322.0K |
| Right-of-use assets | SEK 500.0K | SEK 249.0K |
| Current assets | SEK 600.5M | SEK 94.1M |
| Cash & equivalents | SEK 566.7M | SEK 88.0M |
| Total equity | SEK 555.3M | -SEK 76.8M |
| Non-current liabilities | SEK 190.0K | SEK 6.8M |
| Lease liabilities (non-current) | SEK 190.0K | SEK 0 |
| Current liabilities | SEK 45.5M | SEK 164.4M |
| Lease liabilities (current) | SEK 109.0K | SEK 24.0K |
| Derived metrics | ||
| Return on equity | -30.3% | 280.1% |
| Cash conversion ratio | 1.06× | 0.97× |
| Other reported items | ||
| Accruals Classified As Current | SEK 16.9M | SEK 6.8M |
| Additional Paidin Capital | SEK 1.30B | SEK 503.5M |
| Adjustments For Decrease Increase In Trade and Other Receivables | -SEK 27.5M | SEK 5.6M |
| Adjustments For Depreciation and Amortisation Expense | SEK 1.3M | SEK 1.3M |
| Adjustments For Increase Decrease In Other Liabilities | SEK 8.9M | -SEK 12.7M |
| Adjustments For Increase Decrease In Trade Account Payable | SEK 2.5M | -SEK 546.0K |
| Adjustments For Sharebased Payments | SEK 2.9M | SEK 2.4M |
| Adjustments For Unrealised Foreign Exchange Losses Gains | -SEK 251.0K | SEK 25.0K |
| Cash Advances and Loans From Related Parties | SEK 0 | SEK 124.3M |
| Cash Flows From Used In Operations Before Changes In Working Capital | -SEK 162.2M | -SEK 201.6M |
| Comprehensive Income Attributable To Owners of Parent | -SEK 165.4M | -SEK 206.0M |
| Current Derivative Financial Liabilities | SEK 0 | SEK 665.0K |
| Current Prepayments and Current Accrued Income Including Current Contract Assets | SEK 31.8M | SEK 2.2M |
| Current Tax Expense Income | SEK 750.0K | SEK 505.0K |
| Current Tax Liabilities Current | SEK 7.4M | SEK 7.2M |
| Current Tax Liabilities Noncurrent | SEK 0 | SEK 6.8M |
| Effect of Exchange Rate Changes On Cash and Cash Equivalents | SEK 1.9M | SEK 720.0K |
| Equity and Liabilities | SEK 601.0M | SEK 94.4M |
| Finance Income | SEK 30.5M | SEK 3.6M |
| Fixtures and Fittings | SEK 44.0K | SEK 72.0K |
| Gains Losses On Exchange Differences On Translation Net of Tax | SEK 2.7M | SEK 9.2M |
| General and Administrative Expense | SEK 36.9M | SEK 39.6M |
| Increase Decrease Through Exercise of Warrants Equity | SEK 2.9M | SEK 2.4M |
| Increase Decrease Through Transactions With Owners | SEK 797.5M | SEK 2.3M |
| Interest Paid Classified As Operating Activities | SEK 349.0K | SEK 453.0K |
| Interest Received Classified As Operating Activities | SEK 11.3M | SEK 2.9M |
| Issue of Equity | SEK 715.0M | — |
| Issued Capital | SEK 920.0K | SEK 509.0K |
| Liabilities | SEK 45.7M | SEK 171.2M |
| Other Comprehensive Income | SEK 2.7M | SEK 9.2M |
| Other Current Liabilities | SEK 2.1M | SEK 2.9M |
| Other Current Receivables | SEK 1.9M | SEK 3.9M |
| Other Expense By Function | SEK 3.5M | SEK 772.0K |
| Other Noncurrent Financial Assets | SEK 1.0K | SEK 1.0K |
| Payments For Share Issue Costs | SEK 58.4M | SEK 167.0K |
| Proceeds From Issuing Shares | SEK 715.0M | SEK 0 |
| Research and Development Expense | SEK 136.7M | SEK 166.7M |
| Reserve of Exchange Differences On Translation | SEK 28.7M | SEK 26.0M |
| Retained Earnings | -SEK 772.0M | -SEK 606.8M |
| Revenue From Royalties | SEK 4.6M | SEK 6.0M |
| Share Issue Related Cost | SEK 58.4M | SEK 167.0K |
| Trade and Other Current Payables To Trade Suppliers | SEK 18.9M | SEK 16.4M |
| Trade and Other Payables To Related Parties | SEK 0 | SEK 130.3M |
Every line item above is a fact tagged in Cinclus Pharma Holding AB's annual report
filed in the European Single Electronic Format (ESEF) under the IFRS
taxonomy (ifrs-full) — the income statement, balance sheet
and cash-flow statement as the filer reported them. Values are shown
as-is, in the reporting currency (SEK), without
rescaling; the row labels map to the underlying concept name (e.g.
Revenue → ifrs-full:Revenue, Operating profit →
ifrs-full:ProfitLossFromOperatingActivities, Diluted EPS →
ifrs-full:DilutedEarningsLossPerShare), and any concept
without a curated label is shown under “Other reported items” with its
de-camel-cased tag name. Only consolidated, default-member facts are
shown (segment / dimensional breakdowns are excluded).
“Derived metrics” (free cash flow, margins, ROE, …) are computed from those facts by the same model the U.S. financials pages use — not tagged by the filer.
Source: machine-readable OIM xBRL-JSON aggregated by filings.xbrl.org (XBRL International). Entity identity is resolved by LEI via the public-domain GLEIF register. This is reference data, not investment advice.